SILENOR

Peak

doxepin hydrochloride

NDAORALTABLET
Approved
Mar 2010
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
1

Clinical Trials (1)

NCT01156142Phase 3Completed

Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy

Started Dec 2010
155 enrolled
Head and Neck CancerMucositisOral Complications of Radiation Therapy+1 more

Loss of Exclusivity

LOE Date
Sep 7, 2030
54 months away
Patent Expiry
Sep 7, 2030

Patent Records (5)

Patent #ExpiryTypeUse Code
10238620
May 18, 2027
U-620
9861607
May 18, 2027
U-620
10653662
May 18, 2027
U-620
9486437
May 18, 2027
U-620
12083090
May 18, 2027
U-620